Related Experiment Video
Updated: Jan 20, 2026

Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads
Published on: July 21, 2017
C1q/TNF-related protein 2 (CTRP2) deletion promotes adipose tissue lipolysis and hepatic triglyceride secretion
1Department of Physiology and Center for Metabolism and Obesity Research, School of Medicine, The Johns Hopkins University, Baltimore, Maryland 21205 xia.lei@okstate.edu.
Abstract:
The highly conserved C1q/TNF-related protein (CTRP) family of secreted hormones has emerged as important regulators of insulin action and of sugar and fat metabolisms. Among these, the specific biological function of CTRP2 remains elusive. Here, we show that the expression of human CTRP2 is positively correlated with body mass index (BMI) and is up-regulated in obesity. We used a knockout (KO) mouse model to determine CTRP2 function and found that Ctrp2-KO mice have significantly elevated metabolic rates and energy expenditure leading to lower body weights and lower adiposity. CTRP2 deficiency up-regulated the expression of lipolytic enzymes and protein kinase A signaling, resulting in enhanced adipose tissue lipolysis. In cultured adipocytes, CTRP2 treatment suppressed triglyceride (TG) hydrolysis, and its deficiency enhanced agonist-induced lipolysis in vivo CTRP2-deficient mice also had altered hepatic and plasma lipid profiles. Liver size and hepatic TG content were significantly reduced, but plasma TG was elevated in KO mice. Both plasma and hepatic cholesterol levels, however, were reduced in KO mice. Loss of CTRP2 also enhanced hepatic TG secretion and contributed to impaired plasma lipid clearance following an oral lipid gavage. Liver metabolomic analysis revealed significant changes in diacylglycerols and phospholipids, suggesting that increased membrane remodeling may underlie the altered hepatic TG secretion we observed. Our results provide the first in vivo evidence that CTRP2 regulates lipid metabolism in adipose tissue and liver.
Insights
C1q/TNF-related protein 2 (CTRP2) is linked to obesity. CTRP2 deficiency boosts metabolism and fat breakdown, impacting body weight and lipid profiles in mice.
Area of Science:
- Endocrinology
- Metabolic research
- Molecular biology
Background:
- The C1q/TNF-related protein (CTRP) family regulates metabolism.
- The specific role of CTRP2 in metabolic regulation is largely unknown.
- CTRP2 expression correlates with BMI and obesity.
Purpose of the Study:
- To elucidate the in vivo function of CTRP2 in metabolic regulation.
- To investigate the impact of CTRP2 deficiency on adipose tissue and liver metabolism.
Main Methods:
- Utilized a Ctrp2 knockout (KO) mouse model.
- Analyzed metabolic rates, energy expenditure, and body composition.
- Assessed lipolysis in adipocytes and adipose tissue.
- Examined hepatic and plasma lipid profiles.
- Performed liver metabolomic analysis.
Main Results:
- Ctrp2-KO mice exhibited increased metabolic rates, energy expenditure, reduced body weight, and adiposity.
- CTRP2 deficiency enhanced adipose tissue lipolysis via upregulation of lipolytic enzymes and PKA signaling.
- CTRP2 suppressed triglyceride hydrolysis in adipocytes.
- KO mice showed reduced liver size and hepatic triglyceride content but elevated plasma triglycerides.
- Plasma and hepatic cholesterol levels were decreased in KO mice.
- Loss of CTRP2 increased hepatic triglyceride secretion and impaired postprandial lipid clearance.
Conclusions:
- CTRP2 plays a significant role in regulating lipid metabolism in adipose tissue and the liver.
- CTRP2 deficiency leads to increased energy expenditure and altered lipid profiles.
- Further research into CTRP2's role in obesity and metabolic disorders is warranted.
More Related Videos
Related Concept Videos
Bacterial Translocation and Protein Secretion
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
The Eukaryotic Promoter Region
The Eukaryotic Promoter Region
Gram-negative Bacterial Protein Secretion Systems
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

